《新股消息》瑞丽医美(02135.HK)公开超购385倍上限定价 一手中签率仅3%
瑞丽医美(02135.HK)公布招股结果,发行3.43亿股新股,原先其中10%於本港公开发售,因公开发售录超购385倍,经重新分配後,公开发售股数增至50%,而国际配售初步提呈发售的发售股份仅获足额认购。
每股发售价定於0.4元,为上限定价(招股价介乎0.3元至0.4元),每手10,000股,一手中签率为3%。该股将於下周一(28日)挂牌。独家保荐人为创?融资,联席全球协调人、账簿管理人及牵头经办人为创?证券及千里硕。
公司预期集资净额7,040万元,其中28%将用於作翻新所有现有医疗美容机构并扩张杭州瑞丽、瑞丽天鸽及芜湖瑞丽,另外28%将用於为上海市新建医疗美容机构的资本支出及初始营运成本提供资金,15%将用於浙江省医疗美容机构的潜在战略收购,11%将於作购买医疗美容服务设备及医疗消耗品,8%将用於品牌推广,其余10%将用於一般营运资金及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.